Sarepta Closes ENVISION Enrollment and Will Analyze Blinded Data

Company Sarepta Therapeutics Event Type Clinical development update Modality AAVrh74 gene therapy Asset Elevidys (delandistrogene moxeparvovec) Target DMD (microdystrophin) Disease Area Duchenne muscular dystrophy Summary Sarepta said November 5 it will not reopen enrollment in Phase 3 ENVISION, which studied Elevidys in nonambulatory and late-ambulatory…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *